Adenosine receptors as targets for drug development.
Adenosine is a ubiquitous autacoid that acts on four defined receptors, named A(1), A(2A), A(2B) and A(3). Although the biological activity of adenosine has been known for more than 70 years and the existence of specific receptors for more than 25 years, it is only now that the full potential for drug development is becoming clear. Among some of the conditions for which adenosine receptor-based therapy might be used are Parkinson's disease, hypoxia/ischemia, epilepsy, kidney disease and asthma.
Fredholm
Bertil B
BB
Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden. bertil.fredholm@fyfa.ki.se
D000241:Adenosine / Q000096:biosynthesis / Q000493:pharmacokinetics*; D000818:Animals; D030801:Animals, Genetically Modified / Q000235:genetics / Q000502:physiology; D004195:Disease Models, Animal; D015195:Drug Design; D004341:Drug Evaluation; D006801:Humans; D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1 / Q000187:drug effects* / Q000502:physiology; D013329:Structure-Activity Relationship
D058906:Purinergic P1 Receptor Agonists; D018047:Receptors, Purinergic P1; D000241:Adenosine